Affiliation: University College London
- Emerging therapies in multiple sclerosisRachel Farrell
Department of Neuroinflammation, Institute of Neurology, Queen Square, London, WC1N 3BG, UK
Expert Opin Emerg Drugs 10:797-816. 2005..Many of the treatments discussed in this review are still at early stages of development, but provide exciting potential treatment options; others have proved disappointing in larger extended-phase studies...
- Incorporation of an interferon-β neutralizing antibody assay into routine clinical practiceR A Farrell
University College London, Institute of Neurology, London, UK
Mult Scler 17:1333-40. 2011..With increasing treatment choice for patients, routine NAb testing should be incorporated to aid therapeutic decisions...
- Neutralizing anti-interferon beta antibodies are associated with reduced side effects and delayed impact on efficacy of Interferon-betaR Farrell
National Hospital for Neurology and Neurosurgery, Institute of Neurology, Queen Square, London, UK
Mult Scler 14:212-8. 2008..Interferon-beta (IFNbeta) is a biological therapy which is immunogenic, inducing anti-IFN-beta neutralizing antibodies (Nabs) in some subjects. The frequency of Nabs varies depending on IFN-beta product and the Nab assay used...
- Humoral immune response to EBV in multiple sclerosis is associated with disease activity on MRIR A Farrell
Department of Neuroinflammation, Institute of Neurology, UCL, Queen Square, London, UK
Neurology 73:32-8. 2009..Evidence suggests that Epstein-Barr virus (EBV) plays a role in triggering or perpetuating disease activity in multiple sclerosis (MS)...
- Validating parameters of a luciferase reporter gene assay to measure neutralizing antibodies to IFNbeta in multiple sclerosis patientsRegina Lam
Neuro Immunology Laboratory, University of British Columbia, Vancouver, Canada
J Immunol Methods 336:113-8. 2008..8-29.3%, and the intra-assay coefficient of variation was between 6.3-15.2%. The luciferase assay is reliable, appropriately sensitive and requires less time than the currently available NAb methods...
- Re: Neutralizing antibodies to interferon beta-1b are not associated with disease worsening in multiple sclerosisRachel Farrell
J Int Med Res 36:204-8; author reply 208-10. 2008